Agenus Inc. Reports Q3 2025 Achievements: Regulatory Progress, New Data Revelations, and AI-Driven Collaborations LEXINGTON, Mass. Agenus Inc. (Nasdaq: AGEN) has announced its financial results for the third quarter of 2025, showcasing significant clinical and regulatory advancements. These developments reflect the company s commitment to innovative solut...
In the evolving landscape of oncology and infectious disease management, AIM ImmunoTech Inc. (NYSE American: AIM) has recently captured attention by detailing significant findings from completed clinical trials. The company, primarily known for its innovative immunotherapy, Ampligen (rintatolimod), has contributed to our understanding of treatment modalit...
Recent advancements in the field of oncology have introduced novel therapies aimed at improving survival outcomes for patients with refractory soft tissue sarcomas, a notoriously difficult-to-treat group of tumors. Among these, bio-therapeutic innovations such as Mecbotamab Vedotin (Mec-V), an antibody-drug conjugate (ADC) targeting the AXL receptor, have...
In the ever-evolving landscape of cancer immunotherapy, the latest data unveiled by Coherus Oncology at the Society for Immunotherapy of Cancer (SITC) conference highlights a promising leap forward in precision medicine. CHS-114, a groundbreaking anti-CCR8 cytolytic antibody, demonstrates significant potential in altering the immune microenvironment of he...
: MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on innovative allogeneic invariant natural killer T (allo-iNKT) cell therapies, showcased promising clinical data on its lead candidate, agenT-797, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The findings indicate durable responses and significant immu...
Gilead s ASCENT-07 Study Update: A Mixed Bag Amidst Competitive Pressure in the Pharmaceutical Sector Foster City, California - Gilead Sciences, Inc. (Nasdaq: GILD) has recently provided an update regarding its Phase 3 ASCENT-07 study, which aimed to evaluate the efficacy of Trodelvy (sacituzumab govitecan-hziy) as a first-line treatment in patients with ...
Reykjavik, Iceland and London, UK In a notable stride for the biosimilars industry, Alvotech, a global leader in the development and manufacture of biosimilar medicines, and its partner Advanz Pharma have successfully secured marketing authorizations from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Gobivaz, their biosimilar to S...
Immunocore Presents Phase 1 Data for Hepatitis B Candidate at AASLD s The Liver Meeting In an era marked by remarkable advances in therapeutic strategies, Immunocore has taken a significant step forward in the battle against hepatitis B. At the prestigious American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, held recently, the b...
The landscape of chronic kidney disease (CKD) therapeutics is rapidly evolving, with emerging cell therapies offering new hope for patients suffering from advanced stages of the disease. At the forefront of this innovation is ProKidney Corp. (Nasdaq: PROK), a late clinical-stage cell therapy company dedicated to addressing the dire unmet needs of CKD pati...
Tevogen Bio Expands HLA Coverage for Precision T Cell Therapy in Major Clinical Milestone In a significant advancement in the field of precision medicine, Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has announced a major clinical milestone in its investigational T cell therapy program. The company reported the completion of T cell target identification for a...
for CSIMarket.com Revolution Medicines, Inc., a late-stage clinical oncology company based in Redwood City, California, recently reported its financial results for the third quarter of 2025 and provided significant updates on its pipeline of targeted therapies aimed at treating RAS-addicted cancers. Financial Overview For the quarter ending Septembe...
Pioneering Discussions: Mesoblast Poised for FDA Meeting on Rexlemestrocel-L and Opioid CessationIn a significant step towards revolutionising pain management, Mesoblast Limited (Nasdaq: MESO; ASX: MSB), a global frontrunner in allogeneic cellular medicines for inflammatory diseases, has announced its upcoming meeting with the U.S. Food and Drug Administ...
New York-based Kirby McInerney LLP has announced an investigation into Alvotech, a biotechnology firm listed on NASDAQ under the ticker ALVO, for potential securities fraud. The law firm is scrutinizing whether Alvotech may have violated federal securities laws or participated in any other unlawful business activities.This investigation comes at a crucial...
In the rapidly evolving field of oncology, biopharmaceutical companies are continuously striving to break new ground and deliver innovative therapies to patients confronting cancer. Compass Therapeutics, Inc. (Nasdaq: CMPX) stands at an intriguing intersection of scientific advancement and market dynamics as they recently unveiled promising preclinical da...
Ampligen: A Promising Player in the Fight Against Cancer and Viral Infections AIM ImmunoTech Inc. continues to push the frontiers in the field of immunotherapy, with a series of compelling announcements highlighting the utility of Ampligen (rintatolimod) in combating difficult-to-treat diseases. The latest revelations about Ampligen were showcased in a la...
Alvotech (NASDAQ: ALVO), a leading global biotech company focused on developing and manufacturing biosimilar medicines, has recently made significant announcements concerning its financial performance and strategic engagements. As the company approaches its webcast and conference calls slated for November 2025, the market watches closely to assess the pot...
In the dynamic realm of biopharmaceuticals, regulatory challenges and breakthroughs can dramatically reshape the landscape for companies involved in drug development. Alvotech, a global biotech company specializing in the manufacture of biosimilar medicines, recently encountered significant regulatory hurdles while also celebrating a notable success. This...
Breakthrough and Challenges: Molecular Partners Unveils Pioneering Preclinical Data Amidst Financial Hurdles ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. November 3, 2025 In an exciting development for the field of cancer immunotherapy, Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotechnology powerhouse, has presented furt...
QIAGEN Celebrates 4,000th QIAcube Connect Placement, Reinforcing Commitment to Automated Sample Processing In a major development within the life sciences and diagnostics sectors, QIAGEN N.V., headquartered in Venlo, Netherlands, and Germantown, Maryland, has achieved a significant milestone with the placement of its 4,000th QIAcube Connect instrument. Th...
Breaking New Ground in Myasthenia Gravis Treatment: Positive Phase 2 Data from KYV-101 Study Marks a Milestone for Kyverna Therapeutics Compelling Results Set New Clinical Standard in Generalized Myasthenia Gravis (gMG), Raising Confidence for Upcoming Phase 3 Trial Kyverna Therapeutics Inc. (NASDAQ: KYTX) has recently announced encouraging interim resul...
Expanding Horizons in Cancer Immunotherapy: IN8bio Welcomes The Ohio State University to the INB-100 Phase 1 Clinical Trial The pursuit of innovative cancer treatments takes another encouraging stride as IN8bio, a prominent biotechnology company focused on developing groundbreaking gamma-delta T cell therapies, has announced the expansion of its INB-100 P...
Gilead Sciences, Inc. (Nasdaq: GILD) is positioning itself at the forefront of liver disease research with its upcoming presentation at The Liver Meeting 2025, an event organized by the American Association for the Study of Liver Diseases (AASLD) scheduled for November 7-11 in Washington, D.C. The company plans to unveil notable findings from over 35 acce...
Alector s Advancements and Challenges in Neurodegenerative Therapies: A Comprehensive Update SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 Alector, Inc. (Nasdaq: ALEC), a prominent clinical-stage biotechnology firm, continues to navigate the complex landscape of neurodegenerative disease treatment. The company, which specializes in creating therapies aim...
Transformative Advances in IgA Nephropathy: Vor Bio s Promising Phase 3 Clinical Data Presentation at ASN Kidney Week 2025 In a groundbreaking development that is set to captivate the nephrology community, Vor Bio, a prominent clinical-stage biotechnology entity specializing in the treatment of autoimmune diseases, has announced a significant clinical mil...
Revolutionizing Cancer Treatment: Evaxion s AI-designed Vaccine Achieves Breakthrough Results In a remarkable stride for cancer treatment, Evaxion A/S, a clinical-stage TechBio leader, has announced unprecedented efficacy data from its personalized cancer vaccine, EVX-01, in a Phase 2 trial targeting advanced melanoma. This announcement made on October 17...
In the rapidly evolving field of immuno-oncology, Agenus Inc. (Nasdaq: AGEN) has marked a significant milestone with the presentation of new data demonstrating promising survival outcomes for patients with advanced-stage cancer undergoing treatment with a combination of botensilimab (BOT) and balstilimab (BAL). This novel therapeutic combination has emer...
In recent weeks, the financial theatre surrounding aTyr Pharma, Inc. (NASDAQ: ATYR) has stirred significant concern among its investors, culminating in a class action lawsuit heralded by Pomerantz LLP. As the fiscal tides of the biotechnology sector swell with uncertainty, it becomes imperative for investors who have sustained losses in their investment i...
Exelixis, Inc. (Nasdaq: EXEL) has announced the results of a subgroup analysis from the CABINET phase 3 pivotal trial evaluating the efficacy of CABOMETYX (cabozantinib) against a placebo in patients with advanced neuroendocrine tumors (NET) originating in the lungs and thymus. The findings are scheduled to be presented during the Monday Poster Session: N...
In a pivotal leap for antiviral research and development, Gilead Sciences, Inc. (Nasdaq: GILD) is set to showcase groundbreaking findings at IDWeek 2025, scheduled from October 19-22 in Atlanta, GA. With a comprehensive agenda featuring 34 presentations on the latest advances in HIV, viral hepatitis, respiratory viruses, and other viruses of pandemic pote...
In a significant stride towards revolutionizing treatment options for melanoma and hepatocellular carcinoma (HCC), Replimune Group, Inc. (NASDAQ: REPL), a pioneering clinical-stage biotechnology firm dedicated to novel oncolytic immunotherapies, has showcased robust data from its innovative therapies at prominent oncology conferences in recent months. Dur...
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
